NEW YORK (
CHANGE IN RATINGS
was upgraded to Outperform from Perform at Oppenheimer, which said the stock's risk/reward appears more attractive at current levels. $55 price target.
was initiated with a Buy rating at Citigroup. $7.50 price target. Despite execution issues, the company still has positive end-market exposure, Citigroup said.
was initiated with a Hold rating and $78 price target at Citigroup. The rating is valuation call, as the stock is already pricing in solid growth, Citigroup said.
was upgraded to Buy from Neutral at Goldman Sachs. Company is seeing better end-market demand and has a strong order backlog, Goldman said.
was downgraded to Neutral from Buy at Goldman Sachs, which said it sees downside risk to earnings, especially with the weaker euro.
was upgraded to Buy from Neutral, Janney Montgomery said. $27 price target. New loyalty and digital programs could help drive growth, Janney Montgomery said.
Illinois Tool Works
was upgraded from Equal Weight to Overweight at Barclays Capital, where a new analyst has a $61 price target. Company can grow both internally and through acquisitions, Barclays Capital said.
was upgraded from Hold to Buy at Argus Research. $32 price target. Company is positioned well relative to its peers, Argus said.
was upgraded to Outperform from Market Perform at FBR Capital Markets. $32 price target. The company is in the midst of a massive product cycle, FBR Capital Markets said.
was initiated with an Equal Weight rating and a $15 price target at Morgan Stanley. The company has a high level of debt but is still positioned well for growth in China, Morgan Stanley said.
was downgraded to Market Perform at BMO Capital. $41 price target. Company is seeing increased downtime, BMO Capital said.
was upgraded to Outperform from Market Perform at BMO Capital. Company has limited deepwater exposure to the Gulf of Mexico, said BMO Capital. $37 price target.
was downgraded from Buy to Neutral at Goldman Sachs on valuation.
was initiated with a Hold rating and $31 price target at Citigroup. The company is a market leader but already trades at a premium valuation, Citigroup said.
Waddell & Reed
was downgraded to Hold at Citigroup. $32 price target. Headwinds are mounting against the company's flagship fund, Citigroup said.
STOCK COMMENTS / EPS CHANGES
estimates were cut through 2011 at Credit Suisse. The company is realizing lower sales and using more promotions to clear inventory, Credit Suisse said. Neutral rating and $16 price target.
estimates were raised through 2012 at Goldman Sachs. The company is cutting costs and reducing its workforce. Buy rating and $38 price target.
estimates were raised through 2012 and its price target was lifted to $22 at Morgan Stanley. Broadband growth is driving ARPU expansion, Morgan Stanley said. Equal Weight rating.
estimates were cut through 2011 at Bank of America/Merrill Lynch, which said sales of the specialty chemicals business will dilute earnings. Buy rating and $54 price target.
estimates, target boosted at Barclays Capital. Shares now seen reaching $83. New analyst has also upped estimates, as the company can grow faster than its end-markets, Barclays said. Equal Weight rating.
target was cut to $35 at Morgan Stanley. Company will be hurt by multiple compression across the entire market. Overweight rating.
99 Cents Only
shares now seen reaching $15 at Bank of America/Merrill Lynch. Estimates were also raised, as the company continues to generate margin growth. Underperform rating.
estimates and target were upped at Goldman Sachs. Company has strong sales momentum and margins should continue to expand, Goldman said. Neutral rating and new $43 price target.
estimates and target were raised through 2011 at Barclays Capital. Company boosted guidance and is seeing better margins, Barclays said. Overweight rating and new $24 price target.
Pharmaceutical Product Dev.
estimates were raised through 2012 at Goldman Sachs. Furiex spinoff should help earnings. Neutral rating and $28 price target.
estimates were boosted through 2011 at Morgan Stanley. Management can deliver further growth through the company's joint-venture model, Morgan Stanley said. Equal Weight rating.
estimates, target were raised at Goldman Sachs, which now sees shares reaching $20. Estimates also increased, given the company's positive sales outlook. Neutral rating.
estimates and target were boosted at Goldman Sachs. Shares now seen reaching $21. Estimates also upped, to match the company's new guidance for display revenue growth. Neutral rating.
This article was written by a staff member of TheStreet.com.